Terns Pharma Halts Obesity Drug Development After Mid-Stage Trial Reveals Safety Concerns
Terns Pharmaceuticals has decided to discontinue the development of its experimental obesity drug, TERN-601, following disappointing results from a mid-stage trial. The once-daily oral medication, a GLP-1 receptor agonist, led to a modest 4.6% greater weight loss compared to a placebo over 12 weeks. However, the company concluded that this outcome did not meet the…